220. 急速進行性糸球体腎炎 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 5) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
ALE.F02
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
Corticosteroids
   National Taiwan University Hospital
      2006   Phase 3   NCT00354198   Taiwan
Cyclophosphamid
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
Glucocorticoid
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
Immunosuppressive agents
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom
Methylprednisolone pulse
   Peking University First Hospital
      2016   Phase 2/Phase 3   NCT02647255   China
Pentoxifylline
   National Taiwan University Hospital
      2006   Phase 3   NCT00354198   Taiwan
Pioglitazone
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 3   NCT05946564   France
Rituximab
   Alentis Therapeutics AG
      2023   Phase 2   NCT06047171   Czechia;Denmark;France;Germany;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom